Process for the production of alpha-6-deoxytetracyclines and
申请人:Ranbaxy Laboratories Limited
公开号:US04902447A1
公开(公告)日:1990-02-20
A coordination compound useful as a hydrogenation catalyst, having the formula: ##STR1## wherein Ph is phenyl; R is hydrogen or C.sub.1 -C.sub.4 alkyl; and X is chloro, bromo or iodo. This compound is particularly useful as a homogeneous hydrogenation catalyst in the production of alpha-6-deoxytetracyclines, particularly the antibiotic doxycycline. The desired alpha-6-deoxy product is produced in high yields and stereospecificities, the process requiring the use of minimal quantities of rhodium metal in the hydrogenation catalyst per mole of the 6-methylenetetracycline hydrogenated.
Hydrogenation catalyst useful in the production of
申请人:——
公开号:US04987242A1
公开(公告)日:1991-01-22
A coordination compound useful as a hydrogenation catalyst, having the formula: ##STR1## wherein Ph is phenyl; R is hydrogen or C.sub.1 -C.sub.4 alkyl; and X is chloro, bromo or iodo. This compound is particularly useful as a homogeneous hydrogenation catalyst in the production of alpha-6-deoxytetracyclines, particularly the antibiotic doxycycline. The desired alpha-6-deoxy product is produced in high yields and stereospecificities, the process requiring the use of minimal quantities of rhodium metal in the hydrogenation catalyst per mole of the 6-methylenetetracycline hydrogenated.
Antibacterial activity is exhibited by .beta.-lactams having a sulfate substituent in the 1-position and an acylamino substituent in the 3-position.
具有硫酸取代基在1位和酰胺取代基在3位的β-内酰胺类化合物呈现抗菌活性。
O-sulfated .beta.-lactam hydroxamic acids and intermediates
申请人:E. R. Squibb & Sons, Inc.
公开号:US04337197A1
公开(公告)日:1982-06-29
Antibacterial activity is exhibited by .beta.-lactams having a sulfate substituent in the 1-position and an acylamino substituent in the 3-position.
具有硫酸基取代的β-内酰胺类化合物和3-位置上的酰胺基取代基表现出抗菌活性。
Water-soluble lipophilic contrast agents
申请人:Research Corporation Technologies, Inc.
公开号:US05804164A1
公开(公告)日:1998-09-08
The present invention relates to water-soluble, lipophilic contrast-enhancing agents, pharmaceutical compositions thereof and methods for diagnostic analysis, particularly NMR or MRI analysis using these contrast-enhancing agents. The water-soluble, lipophilic contrast-enhancing agents are chelates of a paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with completing acids which contain at least one short-chain fatty acyl moiety having from about 0 to about 6 carbon atoms in its structure.